Physician profile
Christopher D Milstead
NPI 1932216090
$6,097.81
in general payments reported to CMS, 2019-2025
23 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.46 · 2022: $909 · 2023: $1,709 · 2024: $1,900 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,075 · Education: $43.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,074.81 |
| Education | $43.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,387.08 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $704.07 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $537.38 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $510.52 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $408.58 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $396.96 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $292.59 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $272.74 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $255.55 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $211.05 | 2022-2024 | Rexulti |
| Almatica Pharma LLC | $184.16 | 2024 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $171.92 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $169.91 | 2022-2025 | Trintellix |
| Indivior INC. | $155.86 | 2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $143.05 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $79.14 | 2024 | |
| Idorsia Pharmaceuticals US INC | $53.94 | 2024-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $46.34 | 2024 | Dyanavel Xr |
| Brainsway USA INC | $28.40 | 2025 | Deep Tms System |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Biogen, INC. | $27.19 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $17.15 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $16.96 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Milstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.